IMPORTANT JDD NOTIFICATIONS

Processing update on Case Reports, Brief Communications, Editorials, and Letters to the Editor

Due to an overwhelming number of submission for Case Reports, Letters to the Editor, Brief Communications, and Editorials, please be advised that our processing time will be extended to ensure thorough and quality peer reviews. We apologize for any inconvenience this may cause and thank you for your patience and understanding.

Effective January 1st, 2024, all Letters to the Editor will be published online only, with the title appearing in the Table of Contents of the assigned printed issue, linked by a QR code for direct access. The Letters will appear digitally within the Journal of Drugs in Dermatology electronic (eJDD) issue, will be assigned an individual article citation, and will continue to be indexed on PubMed. For inquiries regarding the citation details, please contact editorial@jddonline.com.

Submission Fee

There is a $25 submission fee payable by credit card only, which covers the societal cost for the per-submission cost to be entered into our submission and tracking software. Please click on the button below to make payment. We use a secure PayPal site to process your credit card payment safely.

If you experience any problems while making a submission payment, email us at support@jddonline.com. Please reference the manuscript number in all correspondence.

The JDD does not currently charge any other processing fees or APC charges. For information on Unrestricted Access please contact Sales. 

JDD AI Ethics Policy

AI does not meet the Journal of Drugs in Dermatology requirements for authorship. AI-based tools such as large language models (LLMs), generative AI, and chatbots (ChatGPT) do not meet ICMJE or COPE authorship requirements, given the need for accountability. Scholarly works must be the author’s own. Authors are accountable for their research papers' validity, integrity, and originality. AI-based tools must be disclosed and clearly explained in all Journal of Drugs in Dermatology publications. Authors should clearly state the use of AI-based tools in their Disclosure statement upon submission.